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Ire1 (Ern1) is an unusual transmembrane protein kinase
essential for the endoplasmic reticulum (ER) unfolded
protein response (UPR). Activation of Ire1 by association
of its N-terminal ER luminal domains promotes autopho-
sphorylation by its cytoplasmic kinase domain, leading to
activation of the C-terminal ribonuclease domain, which
splices Xbp1 mRNA generating an active Xbp1s transcrip-
tional activator. We have determined the crystal structure
of the cytoplasmic portion of dephosphorylated human
Ire1a bound to ADP, revealing the ‘phosphoryl-transfer’
competent dimeric face-to-face complex, which precedes
and is distinct from the back-to-back RNase ‘active’ con-
formation described for yeast Ire1. We show that the
Xbp1-specific ribonuclease activity depends on autopho-
sphorylation, and that ATP-competitive inhibitors stauros-
porin and sunitinib, which inhibit autophosphorylation
in vitro, also inhibit Xbp1 splicing in vivo. Furthermore,
we demonstrate that activated Ire1a is a competent protein
kinase, able to phosphorylate a heterologous peptide sub-
strate. These studies identify human Ire1a as a target
for development of ATP-competitive inhibitors that will
modulate the UPR in human cells, which has particular
relevance for myeloma and other secretory malignancies.
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Introduction
The endoplasmic reticulum (ER) is a major compartment
within the eukaryotic cell responsible for folding of secretory
proteins. Disruption of the balance between secretory protein
synthesis and the folding capacity of the ER activates a
signalling network called the unfolded protein response
(UPR). This attempts to minimise ER overload by transcrip-
tional upregulation of ER chaperones, attenuation of transla-
tion, and activation of ER-associated degradation (ERAD)
pathways (Ron and Walter, 2007; Todd et al, 2008; Zhang
and Kaufman, 2008). If the effort to rectify the imbalance is
not successful, the UPR switches from being pro-survival to
eliciting an apoptotic response (Groenendyk and Michalak,
2005).
Ire1 (a.k.a Ern1) is one of the three transmembrane
‘sensor’ proteins that propagate the signal from the lumen
of the ER to the cytosol. Ire1 consists of an N-terminal
luminal domain, a single-pass transmembrane spanning seg-
ment, and a cytosolic region subdivided into a Ser/Thr
protein kinase domain and a C-terminal endoribonuclease
(RNase) domain with homology to RNaseL (Tirasophon et al,
1998). The ER luminal domain of Ire1 is maintained in its
inactive monomeric state by binding to the ER Hsp70 chaper-
one Bip. Accumulation of misfolded protein in the ER is
thought to cause release of Bip (Bertolotti et al, 2000),
allowing the luminal domain to dimerise (Credle et al,
2005; Zhou et al, 2006). This brings associated cytoplasmic
domains into close proximity on the other side of the ER
membrane, facilitating transautophosphorylation of the
kinase domain, which results in activation of the RNase
domain (Ron and Walter, 2007; Zhang and Kaufman, 2008).
In budding yeast, Ire1 RNase activity is specific for Hac1
mRNA and excises a 252-nucleotide segment in a spliceo-
some-independent manner (Sidrauski and Walter, 1997;
Gonzalez et al, 1999). Human Ire1 excises 26 nucleotides
from Xbp1 mRNA. The spliced transcript Xbp1s encodes a
potent transcriptional activator protein that upregulates ex-
pression of UPR target genes (Yoshida et al, 2001), including
ER chaperones and components of the ERAD pathway
(Friedlander et al, 2000).
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The UPR is activated in many human tumours and is a
mechanism tumour cells exploit to survive hypoxia
(Koumenis, 2006). The Ire1-Xbp1 branch of signalling is
particularly important in multiple myeloma; a cancer result-
ing from malignant transformation of plasma cells. The
survival rate for this cancer is low and thus far there is no
direct curative therapy. Alongside its role in the UPR, Xbp1
controls plasma cell differentiation, and when misregulated,
causes uncontrollable proliferation in myeloma cells (Davies
et al, 2003; Iwakoshi et al, 2003; Carrasco et al, 2007;
Davenport et al, 2007; Todd et al, 2008). As Xbp1s mRNA
levels are directly dependent upon splicing by Ire1, prevent-
ing splicing of Xbp1 mRNA by pharmacological inhibition of
the kinase/RNase activity of Ire1 would appear to be a very
good strategy for selectively targeting multiple myeloma.
However, the lack of a clear mechanistic understanding of
Ire1 function, and in particular the coupling of the kinase and
RNase activities, has clouded the issue. Early work in the
field indicated that Ire1 acts like a typical receptor protein
kinase, undergoing autophosphorylation in trans, following
dimerisation of its ER luminal signalling domain (Shamu and
Walter, 1996; Welihinda and Kaufman, 1996). Furthermore, a
kinase-dead Ire1 was unable to splice substrate RNA (Shamu
et al, 1994; Tirasophon et al, 1998), demonstrating that the
Ire1 phosphoryl-transfer reaction was essential for RNase
activation. However, the remarkable finding that binding of
an ATP-competitive inhibitor to an active site mutant of yeast
Ire1 resulted in RNase activation rather than inhibition has
suggested that it is a conformational change in the kinase
domain induced by nucleotide binding, rather than phos-
phorylation, that provides the trigger to activate the RNase
(Papa et al, 2003). This phenomenon has also been reported
for wild-type yeast Ire1 with the FDA-approved anti-cancer
drug sunitinib (Korennykh et al, 2009).
Recently, there have been several structures of the
C-terminal kinase-RNase domains of yeast Ire1. The first of
these structures (Lee et al, 2008) revealed a symmetric Ire1
dimer arranged in a back-to-back orientation and reported to
be in an RNase ‘active’ conformation, but with the kinase
active sites facing outwards in a manner that would preclude
transphosphorylation. The biological significance of this
arrangement is supported by mutations in the back-to-back
interface that impair RNase activity. A second structure of
yeast Ire1 has been described (Korennykh et al, 2009), in
which the same back-to-back dimer is arranged in a rod-
shaped helical assembly, giving rise to an oligomeric RNase
‘active’ complex. More recently, a yeast Ire1–quercetin–ADP
complex (Wiseman et al, 2010) showed essentially the same
back-to-back orientation that has been seen with the previous
structures. All of the yeast structures have been crystallised
from similar constructs that have an internalB24 amino-acid
deletion within the kinase domain. Furthermore, all the
structures are derived from phosphorylated yeast Ire1 protein
and all describe the RNase ‘active’ conformation of yeast Ire1.
We have now determined the crystal structure of the
cytoplasmic kinase-RNase region of human Ire1a at 2.7 A˚
resolution, in a dephosphorylated state, and in a complex
with Mg2þ -ADP, revealing a face-to-face dimer of the kinase
domains, reminiscent of dimerisation-activated kinases such
as Chk2, LOK, SLK, and DAPK3 (Oliver et al, 2006, 2007; Pike
et al, 2008), in which the kinase active site and activation
segment of the Ire1 protomers are in a suitable orientation
and proximity for transphosphorylation. We believe that this
orientation is an early state ‘phosphoryl-transfer’ competent
conformation of Ire1, which precedes and is distinct from the
RNase ‘active’ back-to-back conformation, that has been
visualised in the yeast structures. Furthermore, our biochem-
ical analysis of human Ire1a shows direct dependence of
RNase activity on autophosphorylation, and that inhibition of
autophosphorylation by ATP-competitors blocks Ire1a RNase
activity in vivo. Our combined structural and biochemical
data show that human Ire1 behaves mechanistically like
a typical receptor protein kinase and that inhibition of
its kinase activity is likely to provide an important new
therapeutic approach to multiple myeloma.
Results
Crystal structure of human Ire1a
A cytoplasmic region of human Ire1a (residues 547–977) was
expressed in insect cells, chromatographically purified, de-
phosphorylated and crystallised by vapour diffusion in a
buffer containing Mg2þ -ADP. Diffraction data to 2.7 A˚ were
collected on station I03 at the Diamond Light Source and the
structure was phased by molecular replacement using the
structure of yeast Ire1. The crystals contain four molecules of
Ire1a in the asymmetric unit (see Materials and methods).
The human Ire1a cytoplasmic region has a very similar
overall structure to those previously determined for yeast Ire1
(Lee et al, 2008; Korennykh et al, 2009; Wiseman et al, 2010)
(Figure 1A), consisting of a bilobal protein kinase fold with
the ATP-binding site in the cleft between the N-terminal
b-sheet lobe and the a-helical C-terminal lobe. A distinct
feature of Ire1 is an addition helical domain, fused to and
structurally continuous with the C-terminal lobe of the
kinase, which provides the sequence-specific ribonuclease
activity by which Ire1 is able to initiate splicing of Xbp1
mRNA (Sidrauski and Walter, 1997; Tirasophon et al, 2000).
The human Ire1a structure is visible from residue 561 to
966, which is 11 residues upstream of the biological
C-terminus. The centralB10 residues (720–729) of the kinase
activation segment, containing a putative phosphorylation
site at Ser724, conserved in yeast Ire1, are disordered. The
activation segment is similarly disordered in the high-resolu-
tion yeast structure (2RIO) and Ire1–quercetin complex struc-
ture (3LJ0), but is ordered in the low-resolution oligomeric
yeast structure (3FBV), where it projects sideways and forms
an interface with another monomer. The conformation and
orientation of the yeast activation segments are markedly
different to human Ire1a (see below). Residues 746–748 in
the human Ire1a kinase domain, at the tip of the loop
connecting helix aF and the short aEF helix carrying the
APE motif, are also disordered. In yeast Ire1, this loop is
substantially longer, and was artificially ‘short circuited’ by
excision of 24 residues in the published structures of the yeast
enzyme, which contributes to crystal lattice interactions. The
connection between helices 3 and 4 in the RNase domain,
which was disordered in the higher-resolution yeast Ire1
structure, is fully ordered in human Ire1a where it has a
helical conformation. Two helical segments (aD0 and aE0)
observed in the yeast Ire1 structures (Figure 1A) do not
occur in human Ire1, where the equivalent segments are
short loops.
Structure of the Ire1 autophosphorylation complex and implications for the UPR
MMU Ali et al
&2011 European Molecular Biology Organization The EMBO Journal VOL 30 | NO 5 | 2011 895
The most significant differences between the human Ire1
and yeast Ire1 monomer structures occur in the N-lobe and
cleft region of the kinase domain. The kinase N-lobe overall is
rotated B61 in human Ire1 with respect to the C-lobe,
compared with the juxtaposition of these lobes in the yeast
structures. Accompanying this is a substantial unravelling of
the N-terminal end of the C-helix in the Ire1 kinase N-lobe,
which adopts a fully ordered extended conformation for
residues 602–611. The rest of this segment, which maintains
a helical conformation, is displaced from its position in
yeast Ire1 by B6 A˚, separating the conserved Lys-Glu ion
pair, required for activity (Huse and Kuriyan, 2002). The DFG
motif, however, has an ‘in’ conformation, consistent with
a catalytically competent state of the protein, with the
carboxylate side chain of Asp711 interacting with the Mg2þ
associated with the bound ADP (Figure 1B and C).
In both the human and the two yeast Ire1 structures (3LJ0,
2RIO), as in many protein kinases in their unphosphorylated
states, the activation segment (Johnson et al, 1996) connect-
ing the protein kinase DFG and APE motifs is disordered.
However, in the lower-resolution phosphorylated yeast Ire1,
an ordered activation segment projects out and away from
the active site and forms an interface with another monomer
in a ‘side-to-side’ orientation. The phosphorylated residues
are intimately involved in this interaction, with the invariant
pSer841 interacting with Lys678 from the opposing monomer,
and pSer840 associating with Asp763 and Glu764 in a nega-
tively charged pocket formed by the aD–aE loop. This
arrangement is not seen in the human structure, since the
orientation of the molecules relative to each other is different
to that seen in all the yeast structures (see below).
In the higher-resolution yeast Ire1 structure, the ordered
N-terminal part of the activation segment, extending from the
DFG motif, is directed away from the bound ADP, in the same
direction as the D24-aEF–aF loop. The C-terminal part lead-
ing into the APE motif and the D24–aEF–aF loop heads in the
opposite direction, so that the ends of the disordered 15
residues of the activation segment, that connects them, are
separated by 430 A˚. By contrast, in human Ire1a, the
N-terminal end of the activation segment immediately follow-
Figure 1 Structure of human Ire1a. (A) Secondary structure cartoons of the crystal structures of cytoplasmic regions of human Ire1a (left) and
yeast Ire1 (middle and right), rainbow coloured blue-red, N-C-terminus. Non-canonical secondary structural elements in the yeast
structures (aD0, aE0), which mediate protein–protein interactions in the different yeast Ire1 crystal lattices, are not conserved in human Ire1a.
Both yeast crystal structures have an engineered loop (D24 loop) connecting a-helices EF and F, from which 24 residues were deleted to obtain
crystals. The equivalent loop in human (and other metazoan) Ire1a is much shorter, and was not modified. A small helix in the C-terminal
RNase domain (a30), which has been suggested to contribute to the catalytic function of this domain is fully ordered in human Ire1a. Human
Ire1a contains an additional b-strand (bC0) formed by the unwinding of the N-terminal end of the kinase domain C-helix, which makes
a b-sheet interaction with the N-terminal end of the activation segment. (B) Close-up of the b-sheet interaction between the bC0-strand and the
N-terminal part of the activation segment immediately following the conserved DFG motif at residues 711–713. This b-sheet interaction directs
the subsequent residues of the activation segment away from the body of the kinase, towards the kinase active site of a second Ire1a molecule
(see below). To our knowledge, this type of interaction, involving the unwinding of the C-helix, has not previously been described in protein
kinases. The tip of the activation segment between residues 720 and 730 is poorly ordered. (C) Close-up of Mg2þ -ADP bound to
dephosphorylated human Ire1a. The DFG motif is in the ‘in’ conformation associated with an activated kinase, and the side chain of
Asp711 in the motif provides a direct ligand interaction with the Mg2þ ion. Electron density mesh is from a Fo–Fc difference Fourier map
calculated with Mg-ADP omitted, and contoured at 3.0s.
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ing the DFG motif projects directly out from the body of the
kinase towards the active site of the opposing monomer,
making an anti-parallel b-sheet with the residues from the
N-terminal end of the C-helix, in their unwound extended
conformation. The C-terminal segment upstream of the APE
motif heads in the same direction, so that the visible tips of
the ordered parts of the human activation segment are only
B9 A˚ apart, and could be readily bridged by the intervening
residues making a reverse loop (Figure 1B).
Ire1 dimerisation and autophosphorylation
In the current models for the activation mechanism of Ire1,
the protein is believed to be held in a monomeric and inactive
state by the ER Hsp70 homologue Bip, which binds to the ER
luminal domain of Ire1 (Bertolotti et al, 2000; Okamura et al,
2000; Kimata et al, 2003). Accumulation of unfolded protein
in the ER promotes release of Bip, permitting dimerisation of
the luminal domains (Credle et al, 2005; Zhou et al, 2006).
This in turn drives oligomeric association and transphosphor-
ylation of the cytoplasmic kinase domain (Shamu and Walter,
1996; Welihinda and Kaufman, 1996), which is an essential
prerequisite for activation of the splicing activity of the
cytoplasmic ribonuclease domain (Tirasophon et al, 2000).
The requirement for formation of dimers (and possibly
higher oligomers) in the activation of Ire1 has dominated the
mechanistic interpretation of the previously described crystal
structures of yeast Ire1 (Lee et al, 2008; Korennykh et al,
2009). In both studies (which utilised extremely similar
constructs incorporating the engineered D24–aEF–aF loop),
an intimate dimer could be identified in the crystal lattice, in
which two Ire1 molecules formed a back-to-back interaction,
with the nucleotide-binding site facing outwards. In both
cases, this dimeric arrangement is further expanded by
helical symmetry to generate the full crystal lattice—in the
high-resolution structure (Lee et al, 2008), the helix has a six-
fold periodicity and is consequently subsumed in the space
group description of the lattice, while in the lower-resolution
structure (Korennykh et al, 2009), the helix has a much
longer periodicity and 14 copies of the back-to-back dimer
constitute the crystallographic asymmetric unit. The arrange-
ment of molecules in the human Ire1a crystals is quite
different to that of the yeast Ire1 structures. Only two
protein–protein interfaces of any substance are observed.
The largest (burying 41700 A˚2 of molecular surface) is an
approximately two-fold symmetric parallel interaction, invol-
ving residues from the kinase domain only, and generates a
‘face-to-face’ dimer arrangement in which the open mouths
of the interlobe clefts, containing bound Mg2þ -ADP, face
each other across the dimer (Figure 2A). The next largest
interface (buryingB1600 A˚2) is an anti-parallel arrangement,
involving the last part of the kinase C-lobe and the ribonu-
clease domain. This arrangement would be incompatible
with the membrane tethering of Ire1 and is likely to be a
crystal lattice contact only.
No interaction resembling the back-to-back dimer seen in
the yeast structures can be identified in the human Ire1a
crystal structure. This maybe in part due to features such as
the aE0 helix, which has a major role in forming the yeast
back-to-back dimer but is absent from human Ire1a (and all
metazoan homologues), and only some of the residues
involved in the back-to-back interaction of the yeast ribonu-
clease domain are conserved in the human enzyme. The
additional side-to-side interface observed in the other yeast
structure (3FBV), and invoked in a formation of a biologically
important high-order Ire1 assembly, also depends upon inter-
actions of a secondary structural element (helix aD0) that is
Figure 2 Face-to-face kinase domain dimerisation of human Ire1a. (A) Human Ire1a forms a dimer in which the kinase active sites of the two
monomers face each other. The activation segment of one monomer is directed towards the other, so that the target substrate residue, Ser724
would come into close proximity of the Mg2þ -ATP bound in the opposite active site, and be phosphorylated by it. This arrangement of Ire1a
molecules provides a straightforward mechanistic model for how dimerisation of Ire1 N-terminal domains in the lumen of the ER would
facilitate association and transphosphorylation of their associated kinase domains on the cytoplasmic side of the membrane.
(B) Autophosphorylation of dephosphorylated dimer interface mutants Q636A and F637A Ire1 as compared with wild type. Both wild-type
and mutant proteins were incubated with 5 mM MgCl and 5 mM ATP at 371C and samples were run at specific time points. Protein samples
were visualised by western blot with generic Ire1a or the phospho-specific pS724-Ire1a.
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absent from human (and other metazoan) Ire1. Whether the
back-to-back orientation exists in the human Ire1 mechanism
remains to be seen. However, what is certain is that the
face-to-face orientation is distinct from the back-to-back
arrangement visualised in the yeast structures. As the
human protein was extensively dephosphorylated prior to
crystallisation, this face-to-face arrangement most likely
represents a functional state that precedes the back-to-back
‘RNase active’ arrangement seen in the phosphorylated yeast
Ire1 structures.
The face-to-face interaction observed in the human Ire1a
crystals provides a straightforward mechanistic explanation
for how the cytoplasmic kinase domains of two Ire1 mole-
cules, brought into close proximity by the association of their
luminal domains on the opposite side of the ER membrane,
might achieve transphosphorylation. The conformation of the
activation segment, bolstered and supported by the partial
unwinding of the C-helix, directs the conserved phosphoryla-
tion target Ser724 at the tip of the activation segment from
one molecule, towards the active site of the opposite Ire1a
molecule in the face-to-face dimer (Figure 2A). This type of
reciprocal face-to-face transphosphorylation has been de-
monstrated structurally and biochemically for a number of
kinases from different branches of the kinome (e.g. Chk2,
LOK, SLK, DAPK3, etc), which like Ire1 are activated by
dimerisation (Oliver et al, 2006, 2007; Pike et al, 2008). The
secondary structural elements involved in the human Ire1a
face-to-face interaction (the b1–b2 hairpin, b3–aC loop, and
aG helix) are present in all Ire1 homologues, and many of the
interfacial residues are invariant or only conservatively
varied in metazoa and yeast, suggesting that, this face-to-
face interaction would be available to all Ire1 homologues.
To test whether this interface is indeed biologically
significant in the autophosphorylation process, we made
mutations in key interfacial residues, Q636A and F637A,
and determined their ability to autophosphorylate as com-
pared with wild type (Figure 2B). Ire1 autophosphorylation
was measured over several time points and using an antibody
developed to measure phosphorylation of Ser724 on the
activation segment of human Ire1a (see below). Both wild-
type and mutant protein were extensively dephosphorylated
prior to incubation with ATP-Mg2.
Mutation of residues implicated in the face-to-face inter-
action observed in the Ire1a crystals, significantly diminishes
the ability of Ire1 to autophosphorylate compared with wild
type, indicating the importance of this interface. In particular,
the mutant Q636A, which disrupts the hydrogen bond with
Asp634 and its Gln637 counterpart in the other monomer,
shows significant retardation of autophosphorylation
especially over the initial 30 min compared with wild type.
The mutation of phenylalanine to a lesser hydrophobic
alanine has less of an impact, but is still significantly slower
to autophosphorylate than wild type.
Ire1a nucleotide binding
Previous structural and biochemical studies have suggested a
mechanisms of Ire1 activation, whereby ADP binding to the
phosphorylated protein promotes a conformational change
that is essential for activation of the ribonuclease activity
(Sidrauski and Walter, 1997; Lee et al, 2008). This notion is
supported by studies, showing that a mutant form of
yeast Ire1 can be directly activated by a mutant-specific
ATP-competitive inhibitor (Papa et al, 2003), and most
radically, that wild-type yeast Ire1 can be directly activated
by the clinically licensed kinase inhibitor sunitinib
(Korennykh et al, 2009). A key feature of this ADP-activation
mechanism is the highly unusual observation, unique to Ire1,
that only the phosphorylated state of Ire1 is competent to
bind ADP (Lee et al, 2008). Nonetheless, the human Ire1a
crystals grown from protein that has been very substantially
dephosphorylated by l-phosphatase (see Materials and meth-
ods) clearly contain Mg2þ -ADP at full occupancy (Figure 1C).
To test this further, we analysed the binding of ADP to human
Ire1a using a thermal-shift assay (Cummings et al, 2006), and
observed clear Mg2þ -dependent ADP binding to depho-
sphorylated protein (Figure 3A and B), fully consistent with
its presence in the crystals. Given the disparity between our
observations and those previously reported, we re-examined
the yeast study, and noted that the unphosphorylated yeast
Ire1, used to demonstrate non-binding of ADP, was a kinase-
dead mutant, inactivated by an alanine mutation of Asp797 in
the catalytically essential HRD motif (Lee et al, 2008). As this
residue is in close proximity to a bound Mg2þ and its
associated solvent molecules, it is likely that the observed
loss of affinity in the Asp797Ala mutant results from
disruption of the structure and electrostatic complementarity
of the Mg2þ -binding site, with consequent loss of affinity
for ADP. The enzymatically dephosphorylated human Ire1a
with a native-binding site, used here, is fully able to bind
Mg2þ -ADP in its unphosphorylated state like all other known
protein kinases.
Figure 3 Nucleotide binding. (A) Thermal-shift analysis of adenine
nucleotide binding to dephosphorylated Ire1a. ATP and AMPPNP
stabilise Ire1 by þ 4.71C and þ 4.11C, respectively, while ADP
shows the tightest binding, stabilising Ire1a by þ 7.21C. Reaction
conditions are given in Materials and methods section. (B) ADP
binding to Ire1a is totally dependent on Mg2þ and in its absence
ADP has minimal effect on Ire1a stability.
Structure of the Ire1 autophosphorylation complex and implications for the UPR
MMU Ali et al
The EMBO Journal VOL 30 | NO 5 | 2011 &2011 European Molecular Biology Organization898
Ire1a phosphorylation activity and inhibition
The involvement of Ire1a in human cancers in general, and
multiple myeloma in particular, identifies it as an important
potential target for therapeutic intervention (Lee et al, 2003).
However, the uncertainties regarding the activation mechan-
ism, and the observation of paradoxical activation rather than
inhibition of the yeast enzyme by ATP-competitive inhibitors,
have placed a question mark over its suitability as a target. To
try and clarify these issues, we developed a phospho-specific
antibody to a peptide derived from residues 718–729 in the
Figure 4 Autophosphorylation and inhibition. (A) Autophosphorylation of dephosphorylated Ire1a monitored by a-pS724-Ire1a phospho-
specific antibody. Ire1a was incubated with 5 mM ATP and 5 mM MgCl2 at 371C for the times indicated. Protein was visualised by SDS–PAGE
with Coomassie Brilliant Blue (CBB) and by western blot with a generic Ire1a antibody or the phospho-specific a-pS724-Ire1a antibody.
(B) Quantitative DELFIA assay measuring autophosphorylation of dephosphorylated Ire1a monitored by a-pS724-Ire1a phospho-specific
antibody. Reaction used 700 nM Ire1a at 371C in the presence of 0.5 mM ATP and 20 mM Mg2þ . The non-linear kinetics are consistent with a
transphosphorylation reaction. (C) Inhibition of Ire1a autophosphorylation by the broad-specificity kinase inhibitor staurosporine, the licensed
anti-cancer drug sunitinib, and ADP. Autophosphorylation reaction was followed by DELFIA assay as in (D) after 2.5 h. (D) Inhibition of Ire1a
autophosphorylation by ADP. Autophosphorylation of previously dephosphorylated Ire1a, indicated by a-pS724-Ire1a western blot, is
progressively inhibited in the presence of increasing concentrations of ADP, and essentially blocked at equimolar ADP to ATP, consistent
with the higher affinity of ADP for the nucleotide-binding site in the unphosphorylated kinase indicated by the thermal-shift analysis (A).
Reactions were carried out in the presence of 5 mM MgCl2. (E) Hetero-phosphorylation of the HTRF biotinylated peptide S2 (200 nM) by
phosphorylated Ire1a (J¼no enzyme; &¼ 50 nM; n¼ 100 nM; K¼ 200 nM; &¼ 400 nM; and m¼ 800 nM) in the presence of 30 mM Mg-
ATP. (F) Concentration-dependent inhibition of Ire1a hetero-phosphorylation activity. Curves are shown for sunitinib (IC50¼ 3.7mM±1.2) and
ADP (IC50¼38mM±17). Staurosporine (data not plotted) had an IC50¼13 nM±8.4. Reactions used 200 nM Ire1a, 200 nM peptide S2, and
30mM ATP. IC50 values are averages of three experiments.
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activation segment of human Ire1a, incorporating a phospho-
serine at 724, and used this to measure autophosphorylation
by Ire1a (see Materials and methods). We were able to
measure robust autophosphorylation on Ser724 with the
previously dephosphorylated human Ire1a when incubated
with Mg2þ -ATP (Figure 4A), which showed non-linear ki-
netic behaviour consistent with a transautophosphorylation
reaction (Figure 4B). This autophosphorylation was sub-
stantially inhibited when the broad-specificity protein
kinase inhibitor staurosporin was included in the reaction
(Figure 4C). Furthermore, we found that ADP was also able to
efficiently inhibit autophosphorylation of Ire1a (Figure 4C
and D), consistent with it being able to bind to the nucleotide-
binding site in the unphosphorylated enzyme contrary to
previous suggestions (see above). Most significantly, we
found that Ire1a autophosphorylation was also inhibited by
sunitinib (Figure 4C).
To date, no other biological substrate for Ire1a phosphor-
ylation other than itself, has been identified. However, using
a commercial homogeneous time-resolved fluorescence assay
system (Cisbio, France), we identified a peptide, S2, that was
efficiently phosphorylated by Ire1a (Figure 4E). While autop-
hosphorylation may be the only significant activity of the
Ire1a kinase in vivo, that it is nonetheless able to phos-
phorylate a heterologous substrate in vitro, shows that
phosphorylated Ire1 retains the conformation required for
the phosphoryl-transfer reaction, including a presumably
ordered activation segment (Johnson et al, 1996), and is
able to bind Mg2þ -ATP and a peptide substrate productively.
As with the autophosphorylation activity, hetero-phosphor-
ylation of the S2 peptide was inhibited by staurosporin, ADP,
and sunitinib (Figure 4F).
Dependence of Ire1a RNase activity on phosphorylation
The truly unique feature of Ire1 is its possession of both
protein kinase and ribonuclease activities. Furthermore, there
is clear evidence that the ribonuclease activity is dependent
on the kinase activity, so that kinase-dead Ire1 mutants, and
mutants in which the activation-segment autophosphoryla-
tion site are mutated, are defective in ribonuclease activity
and UPR signalling (Shamu and Walter, 1996; Welihinda and
Kaufman, 1996; Tirasophon et al, 2000). To analyse this
dependence with the human Ire1a protein used here, we
developed a semi-quantitative assay for in vitro cleavage of
unspliced human Xbp1 mRNA, using an Agilent BioAnalyzer
(Agilent Technologies, Cheshire, UK). We found that phos-
phorylated Ire1a, showing strong immunoreactivity to the
pS724 antibody, was fully able to cleave the Xbp1 mRNA,
whereas Ire1a that was incubated with l-phosphatase and
was devoid of S724 phosphorylation could not (Figure 5A).
The dimerisation interface mutant Q363A showed a mark-
edly decreased ability to autophosphorylate (Figure 2B).
As activation-segment phosphorylation correlated with the
ability to cleave Xbp1 mRNA (see above), we determined
the effect of the Q363A mutation on the RNase activity of
Ire1a using an RNA hairpin-nicking assay. Dephosphorylated
Ire1a-Q363A showed substantially lower RNase activity
than the wild-type protein, when incubated with an Xbp1
mRNA-derived hairpin oligonucleotide in the presence of
Mg-ATP (Figure 5B). The diminished RNase activity of the
autophosphorylation-defective Q636A mutant is fully consis-
tent with a direct dependence of RNase activity on the ability
of Ire1a to autophosphorylate, and argues very strongly that
the observed dimer crystal structure is a key step in the
activation mechanism of Ire1a.
As sunitinib was able to effectively inhibit autophosphor-
ylation of Ire1a, on which the development of Ire1a RNase
activity depends (see above), we sought to determine
whether sunitinib could affect splicing of Xbp1 mRNA
in vivo. We treated H929 and U266 myeloma cells with
tunicamycin, which generates ER stress (Davenport et al,
2007), and is an effective activator of the UPR, and observed
robust increases in the levels of Xbp1s mRNA that could be
detected by real-time quantitative polymerase chain reaction
(PCR) and by gel electrophoresis of reverse transcribed PCR
products 4 h after treatment (Figure 5C and D). When suni-
tinib was added, Xbp1s mRNA levels were substantially
reduced. Xbp1 protein levels, visualised by western blot,
reflected changes in the cellular Xbp1s mRNA levels, with
sunitinib causing a marked decrease in detectable Xbp1
protein (Figure 5E). Thus, inhibition of Ire1a autophosphor-
ylation by sunitinib has the consequence of inhibiting devel-
opment of the autophosphoryation-dependent RNase activity
of Ire1a, and thereby blocks Xbp1 mRNA splicing and
consequent Xbp1 protein expression in myeloma cells.
Discussion
The crystal structure of human Ire1a described here indicates
a face-to-face association of the cytoplasmic kinase domains,
such that the activation segment of one monomer can reci-
procally access and be phosphorylated by the active site of
the other. This orientation is distinct from the ‘RNase active’
back-to-back orientation that has been seen in all the yeast
structures thus far, and represents a ‘phosphoryl-transfer’
competent state. The difference in this conformation is due
to our protein being extensively dephosphorylated prior to
crystallisation and therefore most likely represents an early
stage of the Ire1 mechanism of action, in which the initial
dimerisation of the luminal domains allow the face-to-face
orientation to occur in order to transphosphorylate.
Furthermore, we show that the dephosphorylated protein
is able to bind nucleotide (both ADP and ATP) in the presence
of Mg2þ and rather than Ire1a being allosterically locked in
an active state by ADP binding post-phosphorylation, as
suggested, Ire1a, is fully able to bind ADP in its inactive
unphosphorylated state, and indeed its autophosphorylation,
on which its RNase activity depends, is competitively
inhibited by ADP. Based on our observations and previous
studies, we propose a model (Figure 6) whereby in the
absence of any unfolded protein, Bip associates with the
luminal domains of Ire1. Upon accumulation of misfolded
protein Bip dissociates, which in turn allows dimerisation of
the luminal domains to occur. This juxtaposes the kinase
domains in a face-to-face orientation and upon binding of
nucleotide, strengthens this interaction such that the activa-
tion segment of one monomer can access the active site of the
opposite monomer in trans with the projecting activation
segment supported by formation of an anti-parallel b-sheet
with the residues from the N-terminal end of the C-helix, in
their unwound extended conformation. The effect of the
interfacial mutations on both kinase and RNase activity
strongly suggests that the crystal structure we have obtained
represents a biologically authentic state that is the necessary
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Figure 5 Xbp1 mRNA cleavage by human Ire1a. (A) Elution profiles from Agilent Bioanalyser of (left) untreated Xbp1 mRNA, (middle) Xbp1 mRNA
incubated with dephosphorylated Ire1a, and (right) Xbp1 mRNA incubated with phosphorylated Ire1a. Reaction conditions are given in Materials
and methods section. The peak eluting at a position corresponding to 800 nucleotides in the left and middle panels is the unspliced Xbp1 mRNA,
whereas the pair of peaks eluting at 300 and 500 nucleotides, respectively, in the right panel, corresponds to the two cleaved products of Xbp1
mRNA. The peak at 25 nucleotides in all three panels is a calibration marker. (B) In vitro cleavage activity of Ire1a, wild-type, and Q636A mutant, on
a fluorescently tagged oligonucleotide encapsulating the sequence and secondary structure of a known Ire1a cleavage site in human Xbp1 mRNA.
Cleavage generates a fluorescent species with higher gel mobility. The Q636A mutation, which causes a defect in autophosphorylation, results in a
similar decrease in RNase activity, confirming the dependence of RNase activation on autophosphorylation. (C) Sunitinib inhibits Xbp1 mRNA
splicing in vivo. Myeloma cell lines (U266þH929) were treated with tunicamycin to induce ER stress, in the presence or absence of sunitinib, and
levels of spliced (Xbp1s) and unspliced (Xbp1u) mRNAs in the treated cells were determined by quantitative real-time PCR using LUX primers (see
Materials and methods), and plotted as relative Xbp1u:Xbp1s ratio. In both cell lines, the addition of the Ire1a kinase inhibitor sunitinib significantly
inhibits the splicing of Xbp1 mRNA. (D) Similar results were obtained by RT–PCR amplification. (E) Western blot of protein extracts from cells
treated as in (C), showing inhibition of Xbp1 protein production in ER-stressed cells treated with sunitinib. Actin is shown as a loading control.
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prelude to Ire1 transphosphorylation and its consequent
ability to cleave Xbp1 mRNA.
From the structures observed for phosphorylated yeast
Ire1, the protein must rearrange on autophosphorylation
from the face-to-face orientation to the back-to-back orienta-
tion that is suggested to be the state of the protein required
for RNase activity. Whether this occurs in the human protein
remains to be seen—the residues involved in the yeast dimers
not being conserved. Indeed, we still await an Ire1–RNA
complex structure from either yeast or human that will give
us direct experimental insights into the true RNase ‘active’
conformation. A corollary of the back-to-back arrangement
for the activated Ire1 is that the kinase active sites and
activation segments would be easily accessible to phospha-
tases, providing a facile mechanism for dephosphorylation
and deactivation that returns Ire1 to the ‘ground’ state. Both
the back-to-back and face-to-face interfaces contain residues
that have now been shown to be functionally significant
by mutational studies at least in the species tested, so that
both arrangements may be required for the complete Ire1
mechanistic cycle.
Our structure provides a clear mechanism for how trans-
phosphorylation occurs on the activation segment and has
many precedents in other dimeric protein kinases. What
remains to be defined is a satisfactory mechanistic explana-
tion as to how transphosphorylation of the activation seg-
ment is biochemically coupled to activation of the C-terminal
RNase domain and specifically how autophosphorylation
switches Ire1 from a face-to-face to back-to-back orientation,
if that is indeed the RNase active configuration.
Finally, our biochemical and mutational analysis of human
Ire1a shows direct dependence of RNase activity on autopho-
sphorylation, and that inhibition of autophosphorylation by
ATP-competitors blocks Ire1a RNase activity in vivo, includ-
ing sunitinib that has the conventional and predictable effect
of inhibiting autophosphorylation and consequent RNase
activation, unlike in the yeast system. The demonstration
that an ATP-competitive inhibitor of Ire1a autophosphoryla-
tion can inhibit Xbp1 mRNA splicing in myeloma cells opens
the way for the development of selective and potent new
drugs for the treatment of this disease.
Materials and methods
Cloning, expression, and purification of dephosphorylated
Ire1a
The coding sequence for human Ire1a was PCR amplified from a
human liver cDNA library, with primers designed to encompass the
intact kinase and endoribonuclease domains (residues 547–977).
The PCR product was cloned into a modified version of the pFastBac
vector that contains a 6xHis tag followed by a rhinovirus 3C
protease site. Recombinant baculovirus was prepared using the Bac-
to-Bac (Invitrogen, Paisley, UK) method and were transfected into
Sf9 insect cells. Three rounds of amplification were undertaken, and
at each stage, the baculovirus titer was measured by plaque assay.
Protein was expressed after 3 days of growth at 271C. The cell pellet
was lysed by sonication in 50 mM Hepes pH 7.5, 300 mM NaCl, 10%
glycerol, supplemented with protease inhibitors and centrifuged to
remove cell debris and insoluble material at 40 000 g for 60 min. The
supernatant was then passed through a batch/gravity column
containing 15 ml of talon resin (Clontech) and protein was eluted
off with 300 mM imidazole in a total volume of 50 ml. Ire1 was
dephosphorylated and the his-tag was removed by incubating with
l-phosphatase (300ml at 1.6 mg/ml) in the presence of 2 mM MnCl2
and Rhinovirus 3C protease (PreScission protease, Amersham
Biosciences, 300ml at 2 mg/ml) for 30 min at room temperature
for phosphatase activity and then overnight at 41C. At this stage,
both 1 mM EDTA and 5 mM DDT was added and kept in all
subsequent buffers. Dephosphorylation was confirmed by western
blot using a pSer724 phospho-specific antibody. Human Ire1 was
further purified from contaminants by ion exchange using a Mono-
Q column and by size exclusion chromatography on a Superdex200
column (GE Healthcare).
Cloning, expression, and purification of dephosphorylated
interface mutants of Ire1a
Interface mutants, Q636A, F637A, of the intact kinase and
endoribonuclease domains (residues 547–977) in a modified
version of pFastBac vector, were cloned using a QuickChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) following
the manufacturer’s recommended protocol. Mutant protein was
generated using the baculovirus expression system and purified in
the same way as wild-type protein (as mentioned above), with the
omission of the final purification step of size exclusion chromato-
graphy, due to the relatively low expression level of the mutant
proteins.
Immunoblotting
Protein (5–10mg) was electrophoresed on 4–12% precast Bis-Tris
gels (Invitrogen) and transferred to nitrocellulose. Blocking solu-
tion, (40 ml PBS, 0.1% Tween-20, 2 g of Marvel Dried Milk Powder)
was used to clarify the membrane and 5ml of primary antibody was
added to 10 ml of blocking solution in a 1/2000 dilution, and this
was mixed for 40 min. The membrane was washed three times with
PBS buffer (PBSþ 0.1% Tween-20), followed by addition of the
horseradish peroxidase-conjugated secondary antibody at 1/5000
dilution and mixed for 1 h. This was washed a further three times,
and bands were visualised using ECL chemiluminescent reagents
(GE Healthcare) and developed on Biomax film (Kodak).
Crystallisation
Protein was prepared for crystallisation by concentrating to 9 mg/ml
and incubated with 1 mM ADP, 2 mM MgCl2 on ice for 30 min.
Initial crystallisation experiments were conducted using a Phenix
robot (Art Robbins Instruments) using sparse matrix screens.
Crystals were obtained in two conditions, 2 M (NH4)2SO2, 2.2 M
NaSCN (condition 1) and 25% PEG 3350, 0.2 M (NH4)2SO2, Hepes
pH 7.5 (condition 2). Condition 1 gave crystals that were large and
readily reproducible, but diffracted poorly, whereas condition 2
Figure 6 Autophosphorylation-dependent activation of Ire1a
RNase activity. Model of Ire1 dimer-induced mechanism of action,
highlighting the role of the face-to-face ‘phosphoryl-transfer’ com-
petent state defined here that facilitates transphosphorylation and
phosphorylation-dependent downstream activation of the RNase
activity. Whether the putatively RNase active back-to-back interac-
tion observed in yeast Ire1 structures also occurs in the mammalian
system is yet to be determined—the main structural components,
not being conserved—and the mechanism by which autophosphor-
ylation mediates RNase activation is yet to be directly demon-
strated. Nonetheless, that inhibition of autophosphorylation by an
ATP-competitive inhibitor such as sunitinib blocks consequent
RNase activity provides a means by which therapeutic manipula-
tion of the Ire1 arm of the UPRs might be achieved.
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gave small crystals that were small and hard to reproduce, but did
diffract. Several rounds of microseeding were used to improve
crystals grown from condition 2 that were suitable for data
collection. Crystals were cryoprotected with 30% glycerol and flash
cooled in liquid nitrogen.
Data collection and processing
Data to 2.7 A˚ of the human Ire1a–ADP–MgCl2 complex were
collected on station I03 at Diamond light source from a single
crystal at 100 K. The crystals belonged to the P21 space group (cell
dimensions a¼ 109 A˚, b¼ 83 A˚, c¼ 116 A˚, b¼ 941), with four
molecules in the asymmetric unit. Images were integrated using
MOSFLM (Leslie, 1995), and reduced/scaled using programs from
the CCP4 suite (CCP4, 1994). Human Ire1a crystal structure was
solved by molecular replacement using the program PHASER
(McCoy, 2007), with the yeast Ire1 crystal structure used as the
search model (PDB:2rio). The generated maps were of good quality
especially around the active site and in particular for ADP-Mg2þ
ligand. Phenix.autobuild (Adams et al, 2004) was used for initial
model building and then iterative rounds of manual building in
Coot (Emsley and Cowtan, 2004) and simulated annealing refine-
ment in phenix yielded a structure with good agreement with
observed data and stereochemistry (96% of residues in favoured
and allowed regions in the Ramachandran plot) (see Table I).
Coordinates and structure factors have been deposited in the
Protein Databank with accession code: 3P23. Buried surface areas
were calculated using the PISA server http://www.ebi.ac.uk/msd-
srv/prot_int/pistart
Quantitative measurement of autophosphorylation and
peptide phosphorylation by Ire1a
DELFIA assay buffer (4002-0010), europium-labelled anti-rabbit IgG
(AD0105), and enhancement solution (4001-0010) were obtained
from Perkin-Elmer Life Sciences. Rabbit phospho-specific Ire1a
antibody was raised to a KLH conjugate of the peptide
CLAVGRHS(p)FSRRSG and affinity purified using the non-phos-
phorylated peptide (Open Biosystems, Huntsville, AL). The HTRFs
KinEASE kit (Cisbio Bioassays, Bagnols/Ceze Cedex, France) was
used to detect the peptide phosphorylation activity of the Ire1a
proteins. All other chemicals were from Sigma-Aldrich Co. Ltd.
For the autophosphorylation of Ire1a, non-phosphorylated Ire1a,
ATP, inhibitor or 3% DMSO/buffer were incubated at 371C for 1 h
(40 mM Tris, 20 mM MgCl2, 1 mM DTT pH 7.4) and the reaction
stopped by addition of 20 mM EDTA. The DELFIA assay measured
phosphorylated Ire1a in 96-well plates (Thermo Immulon2-HB)
using a coated-antigen format. The phosphorylation mix (50ml) was
transferred into the microtitre plates and incubated at 41C
overnight. After washing and blocking (5% dried milk/PBS),
phosphorylated Ire1a was detected using specific primary antibody
(165 ng/ml) and europium-labelled anti-rabbit IgG (0.25 mg/ml).
Fluorescence (615 nm) was measured using an Envision multilabel
counter (Perkin-Elmer Life Sciences) using a time-resolved mea-
surement mode.
Peptide phosphorylation was measured using the STK Substrate
2-biotin (Biotinyl-Ahx-RRRLSFAEPG-CONH2) substrate from the
HTRF KinEASE kit. This peptide gave the optimum activity with a
Km of 200 nM. Assays were carried out in low volume, black 384-
well plates (3676 from Corning Life Sciences, MA), with a 10ml
assay volume containing 30 mM ATP (Km¼ 26mM), 600 nM STK
Substrate 2-biotin and 100 nM of phosphorylated or non-phos-
phorylated Ire1. Following incubation at 371C for 1 h, the reaction
was stopped with buffered EDTA, which contained the detection
reagents, streptavidin-XL665 and the STK-antibody labelled with
Eu3þ -cryptate. The resulting TR-FRET signal, calculated as the
fluorescence ratio at 665/620 nm, was read on an Envision and was
proportional to the level of phosphorylation of the peptide.
Thermal shift ligand binding assays
To monitor the binding of ligands to Ire1, the thermal-shift assay
was performed. The method is based on the observation that
ligands change protein thermal stability upon binding to the
protein. This results in a change of the midpoint temperature for
the thermal protein unfolding transition, Tm.
The protein unfolding process is monitored using the
environmentally sensitive dye Sypro Orange. Its quantum yield
increases upon binding to hydrophobic surfaces exposed during
protein unfolding and so does the fluorescence signal.
The thermal-shift assay was conducted in the DNA Engine
Opticon 2 (Bio-Rad), originally designed for RT–PCR. Solutions of
4 mM Ire1, 4.5 X Sypro Orange, 50 mM HEPES pH 7.5, and 200 mM
NaCl final concentration and a volume of 50ml were added to the
wells of a 96-well PCR plate. The final concentration of ADP,
AMPPNP, and ATP was 2 mM for each, with 0 or 5 mM MgCl, for
Sunitinib it was 1 mM with 5 mM MgCl.
Data were analysed with the Excel-based worksheet DSF
analysis. To obtain Tm, a Boltzmann model was used to fit the
fluorescence imaging data using the curve-fitting software Prism
(GraphPad):
I ¼ ðAþ ððB AÞ=ð1 þ expðTm  TÞ=CÞÞ
where I is the fluorescence intensity at temperature T, A and B are
pretransitional and posttransitional fluorescence intensities, respec-
tively, and C is a slope factor.
Data points after the fluorescence intensity maximum were
excluded from fitting. In the absence of ligands (control, with 2%
DMSO for nucleotides and 10% DMSO for Sunitinib), Tm¼T0, and
the ligand-dependent changes in midpoint temperature,
DTm¼TmT0, could be calculated for each ligand.
In vitro full-length XBP1 RNAse cleavage assay
Full-length Xbp1 mRNA was synthesised from cDNA from the
myeloma cell line U266, which only expresses the unspliced form of
Xbp1 (Xbp1u) using the following PCR primers: XBP1-F NDE1 site:
GGAATTCCATATGATGGTGGTGGTGGCAGCCGCG, XBP1-R HindIII
site: CGGACGAAAGCTTTTAGTTCATTAATGGCTTCCAGCTTGG. The
Xbp1 fragment was inserted into TOPO-TA vector (TOPO-TA kit,
Invitrogen) according to the manufacturer’s instructions. Transfor-
mation was performed using XL-blue competent cells (Stratagene).
Following restriction with HindIII, the construct was reverse
transcribed using the MEGAscripts T7 Kit (Ambion, Austin, TX),
and purified using the GeneChips IVT cRNA Cleanup Kit
(Affymetrix, High Wycombe, UK) to produce a full-length Xbp1u
mRNA. In all, 150 ng Ire1a was incubated with 500 ng Xbp1u mRNA
at 371C for 90 min, purified (GeneChip IVT cRNA Cleanup Kit) and
analysed using the Agilent Bioanalyser system (Agilent Technolo-
gies) according to the manufacturer’s instructions.
In vitro hairpin-RNA cleavage assay
Single-stranded RNA mimicking the stem loop structure of Ire1’s
Xbp1 RNA substrate was synthesised with a Cy5 tag at the 50 end:
Cy5ACCUCUGCAGCAGGU (Sigma Genosys). The substrate RNA
was then incubated with wild-type and mutant protein at a
concentration of 10mM in the presence of MgCl2 and ATP at 2 mM
and 1 mM, respectively. The reaction was kept at 371C and at
specific time intervals, samples were taken and run on a 15% TBE-
Urea polyacrylamide gel. Gels were analysed by excitation at
635 nm wavelength using a Fulji FLA5000 laser scanner.
Table I Crystallographic data collection and refinement statistics
Data collection
Space group P21
Cell dimensions, a, b, c, (A˚) 109.8, 83.2, 116.0, b¼ 941
Resolution (A˚) 58.8–2.7
Rsym (%) 9 (32)
I/sI 7.9 (3.2)
Completeness (%) 98.5 (98.5)
Redundancy 3.2
Refinement
Reflections 56 524
Rwork/Rfree 0.24/0.29
RMSD
Bond length 0.003
Bond angle 0.914
No. of atoms
Protein 12 500
Ligand 1554
Water 504
Overall B factor 39
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In vivo XBP1 mRNA splicing
Myeloma cell lines were grown in RPMI1640 GlutaMAXTM
(Invitrogen) supplemented with 10% heat-inactivated fetal calf
serum and 100mg/ml streptomycin. Cultures were kept at 371C in a
humidified atmosphere of 95% air/5% carbon dioxide. Cells were
treated with 100mM tunicamycin to induce stress ±12.5 mM
Sunitinib for 2 and 4 h. Following RNA extraction and cDNA
synthesis, samples were subjected to PCR using 100 pmol/ml LUX
primers (Invitrogen) and the ratio of Xbp1s:Xbp1u was determined.
Primers were as follows: XBP1-s F (FAM-tag): CACCTCTGAGTCCG
CAGCAGG[FAM]G, XBP1-u R (JOE-tag): CAGAGGCTCAGACTACGT
CACCTC[JOE]G, XBP1 common R (unlabelled): CCAGAATGCCCAA
CAGGATA. Thermal-cycling conditions were 10 min at 951C, 40
cycles at 951C for 15 s followed by 1 min at 601C. Samples were run
and analysed on the 7500 Fast time real-time PCR machine (Applied
Biosystems).
To determine relative expression levels of XBP1/XBP1s within a
sample, PCR was performed in a 50-ml platinum Taq reaction
containing 4 pmol of primers (forward 50-CCTTGTAGTTGAGAACC
AGG-30 and reverse 50 GGGGCTTGGTATATATGTGG-30; Invitrogen),
1 unit of platinum Taq DNA polymerase, and 200 mM dNTP. The
temperature profile was at 941C for 2 min, followed by 30 cycles of
941C for 15 s, 601C for 1 min, and 721C for 30 s. Products were run
on 2% agarose gels containing ethidium bromide.
In addition, protein was obtained at similar time points following
drug treatment and subjected to western blotting using standard
conditions. Antibodies were Xbp1 (Biolegend) with an anti-rabbit
secondary (GE Healthcare Ltd).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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